Lexapro (Escitalopram): Uses, Dosage, Side Effects, and Precautions

Lexapro (generic: escitalopram) is a selective serotonin reuptake inhibitor (SSRI) approved by the FDA for major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and adolescents (12+). It is the S-enantiomer of citalopram, offering greater potency and selectivity for the serotonin transporter.

FDA-Approved Indications

  • Major Depressive Disorder (MDD): Adults and adolescents ≥12 years
  • Generalized Anxiety Disorder (GAD): Adults

Common Off-Label Uses

  • Social anxiety disorder (SAD)
  • Panic disorder
  • Obsessive-compulsive disorder (OCD)
  • Post-traumatic stress disorder (PTSD)
  • Premenstrual dysphoric disorder (PMDD)
  • Vasomotor symptoms of menopause

Dosage Guidelines

Dose adjustments: Increase after ≥1 week if needed. Maximum 20 mg/day. Taper gradually on discontinuation.

Common Side Effects (≥5% incidence)

  • Nausea, diarrhea, dry mouth
  • Insomnia or somnolence
  • Fatigue, dizziness
  • Hyperhidrosis (excessive sweating)
  • Sexual dysfunction (delayed orgasm, decreased libido, erectile dysfunction)
  • Weight changes (gain more common long-term)

Serious Risks & Warnings

  • Boxed warning: Increased suicidal ideation/behavior in patients <25 years during initial treatment
  • Serotonin syndrome: With MAOIs, other serotonergic drugs, linezolid, methylene blue
  • QT prolongation: Caution with other QT-prolonging drugs, electrolyte abnormalities
  • Hyponatremia (SIADH): Especially elderly, diuretic users
  • Bleeding risk: With NSAIDs, anticoagulants, antiplatelets
  • Activation of mania: Screen for bipolar disorder
  • Discontinuation syndrome: Dizziness, sensory disturbances, anxiety, irritability—taper over ≥2 weeks

Contraindications & Precautions

  • Concurrent MAOI use (or within 14 days)
  • Pimozide (QT risk)
  • Pregnancy (Category C): Weigh risks/benefits; third-trimester exposure risks neonatal adaptation syndrome
  • Breastfeeding: Excreted in milk; monitor infant
  • Renal/hepatic impairment: Dose adjustment

Monitoring

Assess suicide risk at initiation and dose changes. Monitor weight, sodium, and bleeding signs periodically. Evaluate response at 4–6 weeks; continue 6–12 months after remission to prevent relapse.

Prescription Medications - Related Articles

Health Sciences © https://www.222health.com

ConditionStarting DoseTarget/Max Dose
MDD (adults)10 mg daily10–20 mg daily
GAD (adults)10 mg daily10–20 mg daily
Adolescents (MDD)10 mg daily10–20 mg daily
Elderly/hepatic impairment10 mg daily10 mg daily (max)